PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2003 June; 4(2): 32–43.
Published online 2003 March 3. doi:  10.1208/pt040215
PMCID: PMC2750593

Influence of absorption promoters on pulmonary insulin bioactivity

Abstract

The purpose of this research was to enhance the bioactivity of insulin by the pulmonary route using a combination of absorption promoters. Aliquots (100 μL) containing 1.0 IU/kg to 7.0 IU/kg doses of porcine insulin solutions with different classes of absorption promoters and combinations of these at 3 concentration levels were instilled intratracheally to the anesthetized rats. Blood concentrations of glucose were measured at specific time points. Out of 3 concentration levels of each of the absorption promoters used, the formulations having the leastconcentration with the maximum percentage of blood glucose reduction were selected for combining absorption promoters, and their pharmacodynamic parameters related to insulin absorption were determined. The pharmacodynamics of porcine insulin following subcutaneous administration of increasing doses were also determined. The relative pulmonary bioactivity of insulin in phosphate buffer pH 7.4 and citrate buffer pH 3.5 was 11.36%±1.27% and 43.20% ±2.48%, respectively, compared to subcutaneous administration. Relative pulmonary bioactivity of 155.60%±5.19% was obtained when oleic acid sodium salt, sodium tauroglycocholate, bestatin, and chymostatin were coadministered in citrate buffer pH 3.5 solution. However, only 61.91%±3.21, 67.09%±3.23%, 67.24%±2.11%, and 69.84%±3.02% were obtained, respectively, upon incorporation of these absorption promoters individually. Absorption promoters in combination have significant potential for increasing the pulmonary bioactivity of insulin. These studies support the argument that pulmonary administration of insulin is a viable alternative to subcutaneous administration for diabetic patients.

Keywords: insulin, combination of absorption promoters, blood glucose reduction, relative pulmonary bioactivity, pharmacodynamics

Full Text

The Full Text of this article is available as a PDF (667K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Jiang G, Qiu W, DeLuca PP. Preparation and in vitro/in vivo evaluation of insulin-loaded poly(acryloyl-hydroxyethyl starch)-PLGA composite microspheres. Pharm Res. 2003;20:452–459. doi: 10.1023/A:1022668507748. [PubMed] [Cross Ref]
2. Hildebrand GE, Tack TW. Microencapsulation of peptides and proteins. Int J Pharm. 2000;196:173–176. doi: 10.1016/S0378-5173(99)00415-9. [PubMed] [Cross Ref]
3. Haeckel S, Sachse S, Albayrak C, Müller RH. Preparation and characterization of insulin-loaded microcapsules produced by the induced phase separation method. In: Proceedings of the World Meeting, 1998 APGI/APV, Paris.
4. Wall DA. Pulmonary absorption of peptides and proteins. Drug Deliv. 1995;2:1–20. doi: 10.3109/10717549509031346. [Cross Ref]
5. Stanley SD. Delivery of peptide and non-peptide drugs through the respiratory tract. Pharm Sci Tech Today. 1999;12:450–459.
6. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst. 1995;12:151–231. [PubMed]
7. Patton JS, Trinchero P, Platz RM. Broavailability of pulmonary delivered peptide and protein: interferon alpha, calcitonin and parathyroid hormones. J Control Release. 1994;28:79–85. doi: 10.1016/0168-3659(94)90155-4. [Cross Ref]
8. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276:1868–1871. doi: 10.1126/science.276.5320.1868. [PubMed] [Cross Ref]
9. Berelowitz M, Becker G. Inhaled insulin: clinical pharmacology and clinical study results. Respir Drug Deliv. 2000;7:151–154.
10. Clauson PG, Balent B, Okikawa J, et al. PK-PD of four different doses of pulmonary insulin delivered with AERx Diabetes management system. Respir Drug Deliv. 2000;7:155–161. doi: 10.1080/10717540050120197. [Cross Ref]
11. Adjei A, Hui J, Finley R, Lin T, Fort F. Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: some pharmacokinetic and pre-clinical issues. Int J Pharm. 1994;107:57–66. doi: 10.1016/0378-5173(94)90302-6. [Cross Ref]
12. Garber RA, Cappelleri JC, Kourides IA, Gelgend RA, Chandler LP, Gorkin L. Improved patient satisfaction with inhaled insulin in subjects with Type I diabetes mellitus: results from a multi-center randomized controlled trial. Diabetes. 1999;48(Suppl 1):A13–A13.
13. Shyler JS, Cefalu IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA. Efficacy of inhaled insulin in Type 1 diabetes. Lancet. 2002;357:331–335. [PubMed]
14. Fukuda Y, Tsuji T, Fujita T, Yamamoto A, Muranishi S. Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors. Biol Pharm Bull. 1995;18:891–894. [PubMed]
15. Suarez S, Garcia L, Sarubbi D, et al. Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. Pharm Res. 2001;18:1677–1684. doi: 10.1023/A:1013362227548. [PubMed] [Cross Ref]
16. Okumura K, Iwakawa S, Yoshida T, Seki T, Komada F. Intratracheal delivery of insulin: absorption from solution and aerosol by rat lung. Int J Pharm. 1992;88:63–73. doi: 10.1016/0378-5173(92)90304-K. [Cross Ref]
17. Liu FY, Shao Z, Kildsig DO, Mitra AK. Pulmonary delivery of free and liposomal insulin. Pharm Res. 1993;10:223–232. doi: 10.1023/A:1018934810512. [PubMed] [Cross Ref]
18. Enna SJ, Schanker LS. Absorption of saccharides and urea from the rat lung. Am J Physiol. 1972;222:409–414. [PubMed]
19. Hyvärinen A, Nikkilä EA. Specific determination of blood glucose with o-toluidine. Clin Chim Acta. 1962;7:142–143. doi: 10.1016/0009-8981(62)90133-X. [PubMed] [Cross Ref]
20. Gibaldi M, Perri D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker; 1982.
21. Devore JL, Farnum NR. Applied Statistics for Engineers and Scientists. Pacific Grove, CA: Brooks/Cole Publishing Co; 1999. pp. 394–398.
22. Brange J, Anderson L, Laursen ED, Meyn G, Resmussen E. Towards understanding insulin fibrillation. J Pharm Sci. 1997;86:517–524. doi: 10.1021/js960297s. [PubMed] [Cross Ref]
23. Brange J, Langkjaer L. Chemical stability of insulin, III: influence of excipients, formulation, and pH. Acta Pharm Nord. 1992;4:149–158. [PubMed]
24. Hirai S, Ikenaga T, Matsuzawa T. Nasal absorption of insulin in dogs. Diabetes. 1978;27:296–299. doi: 10.2337/diabetes.27.3.296. [PubMed] [Cross Ref]
25. Hirai S, Yashiki T, Mima H. Effect of surfactants on the nasal absorption in rats. Int J Pharm. 1981;9:165–172. doi: 10.1016/0378-5173(81)90009-0. [Cross Ref]
26. Gordon GS, Moses AC, Silver RD, Flier JS, Carey MC. Nasal absorption of insulin enhancement by bile salts. Proc Natl Acad Sci USA. 1985;82:7419–7423. doi: 10.1073/pnas.82.21.7419. [PubMed] [Cross Ref]
27. McMartin C, Hutchinson LEF, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci. 1987;70:535–540. doi: 10.1002/jps.2600760709. [PubMed] [Cross Ref]
28. Yamomoto A, Hayakawa E, Lee HL. Insulin and pro-insulin proteolysis in mucosal homogenate of the albino rabbit: implications in peptide delivery from non-oral routes. Life Sci. 1990;47:2465–2474. doi: 10.1016/0024-3205(90)90492-A. [PubMed] [Cross Ref]
29. Khan MJ, Lakshminarayanaiah N, Trotman BW, Chun P, Kaplan SA, Margulies C. Calcium binding and bile salt structure. Hepatology. 1982;2:732–732.
30. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular Biology of the Cell. 2nd edition. New York: Garland Publishing Inc.; 1989. Cell adhesion, cell junctions and the extracellular matrix; pp. 791–836.
31. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev. 1999;35:235–247. doi: 10.1016/S0169-409X(98)00074-X. [PubMed] [Cross Ref]
32. Hooper NM. Ectopeptidases. In: Audus KL, Raub TJ, editors. Biological Barriers to Protein Drug Delivery. Pharmaceutical Biotechnology. New York, NY: Kluwer Academic/Plenum Publishers; 1993. pp. 23–50.
33. Takeyama M, Ishida T, Kokubu N, et al. Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors. Pharm Res. 1991;8:60–64. doi: 10.1023/A:1015878222769. [PubMed] [Cross Ref]
34. Okumura K, Komada F, Ryohei H. Fate of porcine and human insulin at the subcutaneous injection site, I: degradation and absorption of insulin in the rat. J Pharmacobiodyn. 1985;8:25–32. [PubMed]
35. Hochman J, Artursson P. Mechanism of absorption enhancement and tight junction regulation. J Control Release. 1994;29:253–267. doi: 10.1016/0168-3659(94)90072-8. [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists